Nanjing Vazyme Biotech Co., Ltd (SHA:688105)

Market Cap	8.35B -8.2%
Revenue (ttm)	1.41B +3.8%
Net Income	-14.70M
EPS	-0.03
Shares Out	397.73M
PE Ratio	n/a
Forward PE	51.20
Dividend	0.50 (2.38%)
Ex-Dividend Date	n/a

Volume	2,927,401
Average Volume	2,041,717
Open	21.00
Previous Close	20.99
Day's Range	20.15 - 21.00
52-Week Range	18.17 - 26.77
Beta	0.74
RSI	65.45
Earnings Date	Apr 23, 2026

About Nanjing Vazyme Biotech

Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real-time PCR (qPCR), one-step RT-PCR/RT-qPCR, nucleic acid electrophoresis, genome editing techniques, isothermal amplification, and instant granules; and...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 2,754
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688105

Financial Performance

In 2025, Nanjing Vazyme Biotech's revenue was 1.38 billion, a decrease of -0.00% compared to the previous year's 1.38 billion. Losses were -16.61 million, -8.18% less than in 2024.